scholarly journals The diagnostic and prognostic values of MicroRNA-196a in cancer

2020 ◽  
Author(s):  
Mengqiu Xiong ◽  
Ping Wang ◽  
Bei Pan ◽  
Junjie Nie ◽  
Shukui Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Adrenocortical Carcinoma ◽  
Tumor Tissue ◽  
Published Data ◽  
Lower Grade ◽  
Diagnostic Biomarker ◽  
Lower Grade Glioma ◽  
Diagnostic Values

MicroRNA-196a (miR-196a) was previously reported to be upregulated in cancers, and it has the diagnostic and prognostic values in cancers. Whereas, the conclusion was still unclear according to the published data. To assess such roles of miR-196a in cancers, this study was conducted based on published data and online cancer related databases. To identify the relevant published data, we searched articles in databases and then the relevant data was extracted to evaluate the correlation between miR-196a expression and diagnosis, prognosis for cancer patients. The pooled results showed that miR-196a was a valuable diagnostic biomarker in cancer (AUC=0.87, 95%CI: 0.84-0.90; sensitivity=0.73, 95%CI:0.64-0.81; specificity=0.90, 95%CI:0.81-0.95), which was consistent with the data from databases (breast cancer: miR-196a-3p: AUC=0.77, 95%CI: 0.74-0.79; miR-196a-5p: AUC=0.71, 95%CI: 0.66-0.75; pancreatic cancer: miR-196a-3p: AUC=0.80, 95%CI: 0.73-0.87; miR-196a-5p: AUC=0.61, 95%CI:0.51-0.71). In addition, the pooled result revealed that elevated miR-196a expression in tissues (HR=2.54, 95%CI: 1.79-3.61, PHeterogeneity =0.000, I2=75.8%) or serum/plasma (HR=4.06, 95%CI: 2.67-6.18, PHeterogeneity =0.668, I2=0%) was an unfavorable survival biomarker, which was consistent with the data from databases (adrenocortical carcinoma: HR=5.70; esophageal carcinoma: HR=1.93; brain lower grade glioma: HR=2.91; GSE40267: HR=2.47, 95%CI: 1.2-5.07; TCGA: HR=1.82, 95%CI: 1.21-2.74; GSE19783: HR=4.24, 95%CI:1-18.06). In short, our results demonstrated that miR-196a in tumor tissue or serum/plasma could be used as a prognostic and diagnostic values for cancers.

scholarly journals The Diagnostic and Prognostic Values of MicroRNA-196a in Cancer

2020 ◽  
Author(s):  
Mengqiu Xiong ◽  
Ping Wang ◽  
Bei Pan ◽  
Junjie Nie ◽  
Shukui Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Pancreatic Cancer ◽  
Published Data ◽  
Lower Grade ◽  
Diagnostic Biomarker ◽  
Survival Prognosis ◽  
Statistical Software ◽  
Lower Grade Glioma ◽  
Diagnostic Values

Abstract BackgroundmicroRNA-196a (miR-196a) was previously reported to be upregulated in cancers, and has the diagnostic and prognostic values in cancers. Whereas, the conclusion was still unclear according to the published data. To assess such a role of miR-196a in cancers, this study was conducted based on published data. MethodsTo identify the relevant published data, we searched articles in databases and then the relevant data was extracted to assess the correlation between miR-196a expression and diagnosis and survival for cancer patients, all data was analysis with the statistical software STATA. ResultsThe pooled results showed that miR-196a was a valuable diagnostic biomarker in cancer (AUC=0.87, 95%CI: 0.84-0.90; sensitivity=0.73, 95%CI:0.64-0.81; specificity=0.90, 95%CI:0.81-0.95), which was consistent with the data from databases (breast cancer: miR-196a-3p: AUC=0.77, 95%CI: 0.74-0.79; miR-196a-5p: AUC=0.71, 95%CI: 0.66-0.75; pancreatic cancer: miR-196a-3p: AUC=0.80, 95%CI: 0.73-0.87; miR-196a-5p: AUC=0.61, 95%CI:0.51-0.71). In addition, miR-196a in tissues was an unfavorable survival prognosis biomarker (HR=2.54, 95%CI: 1.79-3.61, PHeterogeneity =0.000, I2=75.8%) and serum or plasma (HR=4.06, 95%CI: 2.67-6.18, PHeterogeneity =0.668, I2=0%), which was consistent with the data from databases (adrenocortical carcinoma: HR=5.70; esophageal carcinoma: HR=1.93; brain lower grade glioma: HR=2.91; GSE40267: HR=2.47, 95%CI: 1.2-5.07; TCGA: HR=1.82, 95%CI: 1.21-2.74; GSE19783: HR=4.24, 95%CI:1-18.06). ConclusionOur results demonstrated that miR-196a acts as a tumor suppressor with prognostic and diagnostic values for cancer.

scholarly journals Survival Analysis: A Hospital Based Retrospective Life Span Study of Breast Cancer Patients after First Recurrence

2020 ◽  
Vol 2 (1) ◽  
pp. 1-8
Author(s):  
Madiha Liaqat ◽  
◽  
Waqas Fazil ◽  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Life Span ◽  
Survival Time ◽  
Cancer Patients ◽  
Cox Regression ◽  
Molecular Subtype ◽  
Published Data ◽  
Lower Grade ◽  
Breast Cancer Patients

Background Overall survival of breast cancer patients has been calculated many times but there is no precise research available regarding the survival time of breast cancer patients after recurrence. We investigated the effects factors on mortality due to breast cancer. Methods All Factors were analyzed using statistical tools and techniques to find out rate of mortality after recurrence. Descriptive statistics, cox proportional hazard models were used to find statistical significant variables. In the present study recurrence is considered as an important event which may play a role in study of breast cancer progression. In this study, we evaluated breast cancer risk factors in relation to mortality due to this disease among 1028 women with breast cancer in Lahore, Pakistan. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between risk factors and mortality due to breast cancer were estimated in subtype-specific Cox regression models. Results Survival of breast cancer patients depends upon many factors. A total of 581 alive and 447 deaths due to breast cancer occurred during a median follow-up period of 1977 days. Median survival time after recurrence was 3 years. Significant factors were included post- menopausal women who diagnosed and had recurrence at the age < 45 of molecular subtype estrogen receptor positive, progesterone receptor negative, Her2.neu positive with tumor size ≥ 3 & involved lymph nodes >5. Radiotherapy has increased life span of patients even after recurrence. Conclusion Younger women had higher risk of mortality after recurrence even gone through chemotherapy while lower grade tumor had good prognosis. Radiotherapy played a major role in increasing life time of breast cancer women after recurrence. Our findings are consistent with those from previously published data.

PGR and TUG1 overexpression: A putative diagnostic biomarker in breast cancer patients

Gene Reports ◽  
2020 ◽  
Vol 21 ◽  
pp. 100791 ◽  
Author(s):  
Saghar Mashhadizadeh ◽  
Mohammad Tavangar ◽  
Aliasghar Fallahiyan Javani ◽  
Mohamad Davood Rahimian ◽  
Mansoureh Azadeh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Diagnostic Biomarker ◽  
Breast Cancer Patients

scholarly journals Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients

BMC Cancer ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Takashi Takeshita ◽  
Yutaka Yamamoto ◽  
Mutsuko Yamamoto-Ibusuki ◽  
Aiko Sueta ◽  
Mai Tomiguchi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Tissue ◽  
Breast Cancer Patients

The analysis of NBS-1 gene mutation [657del(5)] in exon 6 in the population of 472 sporadic breast cancer patients in the Czech Republic

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 20087-20087
Author(s):  
J. Melter ◽  
G. Pazdrova ◽  
F. Janku ◽  
Z. Kleibl ◽  
J. Novotny ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Internal Control ◽  
Sporadic Breast Cancer ◽  
Breast Cancer Incidence ◽  
Published Data ◽  
Agarose Gel ◽  
Breast Cancer Patients ◽  
Blood Monocytes ◽  
Specific Band

20087 Background: Nijmegen breakage syndrome (NBS) caused by mutation [657del(5)] in exon 6 of NBS-1 is an autosomal recessive disorder with microcephaly, immunodeficiency, radiosensitivity, and predisposition to lymphoid malignancies. Recently, high frequency of NBS-1 mutation was found in some Slavic populations. Because NBS-1 heterozygotes may have high incidence of neoplastic changes, there is an urgent need to clarify the role of NBS-1 mutation in breast cancer carcinogenesis. Methods: We analyzed the NBS-1 status in 472 sporadic breast cancer patients treated in the Department of Oncology, Charles University Prague. DNA was extracted from peripheral blood monocytes. Subsequently two PCRs for each sample were carried out. Reaction was visualized using electrophoresis on agarose gel. Agarose gel wells with both the NBS-1 gene-specific band and internal control band were interpreted as positive. Wells with internal control only were interpreted as negative. PCR from samples giving neither an internal control band nor specific band were repeated. DNA samples obtained from a previously typed NBS family were used as a positive control. Results: Based on previously published data we expect to find at least 5 mutation carriers. Surprisingly, in our population of 472 subjects there was no mutation identified. Conclusions: Based on results of this study there is no relationship between NBS-1 mutation and breast cancer incidence. Acknowledgment: The study was supported in part by the RASO grant from Czech Society of Oncology, and MSM0021620808. No significant financial relationships to disclose.

Chemokine CXCL13 is overexpressed in the tumor tissue and in the peripheral blood of breast cancer patients

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 22029-22029
Author(s):  
D. Atanackovic ◽  
Y. Hildebrandt ◽  
A. Marx ◽  
Y. Cao ◽  
C. Bokemeyer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Tumor Tissue ◽  
Breast Cancer Patients

Breast cancer patients' rights: How can they be respected in Iran?

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 81-81
Author(s):  
Azadeh Joulaee ◽  
Soodabeh Joolaee ◽  
Naser Bahrani ◽  
Maryam Kadivar ◽  
Mojgan Kalantari
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Care Delivery ◽  
Frozen Section ◽  
Breast Cancer Incidence ◽  
Conservative Surgery ◽  
Published Data ◽  
Breast Cancer Patients ◽  
Patients Rights ◽  
Trucut Biopsy

81 Background: The revolutionary concept in breast cancer diagnosis and treatment has significantly changed many aspects of cancer treatment in favor of patients' rights. The best useful targeted treatment is offered to them with the least harm and invasion. As the most common cancer, breast cancer incidence is 24/100, 000 or one-fourth of all new cancers. The aim of this study is to compare the international rights for breast cancer patients with actual situation in Iran. Methods: All published data in Iran are reviewed since 2001 to 2012 to see the actual care in Iran. Codification of new radiology, surgical and pathologic procedure and insurance coverage are searched through available national references. These data are compared with international references. Results: Diagnosis is done by excisional/incisional biopsy or frozen section. Trucut biopsy is done in a low minority of cases. Insurance system does not cover vacuum assisted biopsy. Only mastectomy and axillary dissection are accepted by insurance. No codification exists for conservative surgery, oncoplastic surgery and sentinel node biopsy and the rate for these surgeries are low. Breast reconstruction, conservative surgery as bilateral mammoreduction, and symmetrization of controlateral breast are considered as cosmetic surgery with no coverage. The majority of cases are treated in general surgical wards. There are very few breast nurses and few centers for rehabilitation, lymphedema treatment, and psychological support of survivor. Conclusions: The ministry of health insists on full respection of the patient’s rights in medical practice. The new rights of breast cancer patients based on new treatment strategy are not highlighted in Iran. Valid evidence must be provided for policy makers about the rights of these vulnerable patients to consider them in Iranian health care delivery system. Specialized breast unit can improve significantly the quality of breast cancer care toward the patients' right. Pre-operative confirmation of cancer by trucut biopsy seems to be the key point. This gives the patient the opportunity to know more about the disease and to search for the best therapeutic plan according to international guideline.

Sign in / Sign up

Export Citation Format

Share Document